Sign In
Buy GLP
$48.46
-0.170 (-0.350%)
At Close: Jul 29, 2026
Mag7, AI and GLP-1: Roundhill CEO on the hottest ETFs to watch
02:51pm, Thursday, 12'th Sep 2024
Dave Mazza, Roundhill Investments CEO, joins CNBC's Bob Pisani on “Halftime Report's” “ETF Edge” segment to discuss the firms' three ETFs following the Mag7, AI and GLP-1 themes.
Modular Medical Announces Finalization of Protocol for GLP-1 Personalized Metabolic Therapy Study Utilizing the MODD1 Platform
08:00am, Wednesday, 11'th Sep 2024
-Proof of Concept Study in Rapid Acting GLP-1 to commence in October 2024 with data expected in November 2024 -Pre-clinical study to explore use of MODD1 pump as a personalized delivery system for peo
Mondelez is trading as if GLP-1 drugs don't exist, says Jim Cramer
08:20pm, Tuesday, 10'th Sep 2024
'Mad Money' host Jim Cramer looks at how Mondelez is dealing with GLP-1 drugs.
Obesity drugs in kindergarten? Novo Nordisk GLP-1 drug works for kids as young as 6, study finds.
06:02pm, Tuesday, 10'th Sep 2024
Amid an ongoing debate over what role, if any, GLP-1 medications should play in treating children who are still in elementary school, researchers have concluded that a Novo Nordisk obesity drug may be
Company announcement – No. 44 / 2024 Zealand Pharma announces positive topline results from 13-week Phase 1b multiple ascending dose clinical trial with GLP-1/GLP-2 receptor dual agonist dapiglutide
Meet with Modular Medical CEO, Jeb Besser There are more than 3 million individuals who use daily insulin to help with the care of Diabetes in the US.100% of patient population require daily insulin i
TAMPA, Fla. , Sept. 4, 2024 /PRNewswire/ -- Integrated Ventures Inc. (OTCQB: INTV), a holdings company, focused on e-commerce technology, digital assets and consumer-focused investments, is excited to
4 Stocks That Boosted Their Bottom Line with Beef
07:29am, Wednesday, 04'th Sep 2024
The advent of GLP-1 weight-loss treatments has inadvertently underscored the importance of protein in mitigating muscle loss. While taking GLP-1 meds may be out of reach of many consumers due to exorb
3 GLP-1 Stocks to Buy Now For Big Long-Term Gains
09:12am, Sunday, 01'st Sep 2024
The surge in interest investors have displayed for companies delivering weight loss drugs has been impressive.
Viking Therapeutics: GLP-1/GIP Receptor Agonist And Its Competitive Landscape
06:32am, Friday, 30'th Aug 2024
Viking Therapeutics' VK2735, a dual GLP-1/GIP receptor agonist, shows promising results in Phase II trials for obesity treatment with potential for both subcutaneous and oral formulations. Despite com
The GLP-1 Products and Players - Expanding a new Era of Pharmaceutical Products for Diabetes and Weight Loss
10:30am, Wednesday, 28'th Aug 2024
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - August 28, 2024) - Investorideas.com, a go-to investing platform covering health and wellness and biotech stocks issues a snapshot lo
Integrated Ventures Announces Strategic Entry Into Health & Wellness Industry with Focus on GLP-1 Products
08:43am, Wednesday, 28'th Aug 2024
TAMPA, Fla. , Aug. 28, 2024 /PRNewswire/ -- Integrated Ventures, Inc. (OTCQB: INTV), a diversified portfolio holdings company, is excited to announce its strategic entry into the rapidly expanding he
Lemonaid Health Now Offering GLP-1 Medication Through Weight Loss Membership Program
07:30am, Wednesday, 28'th Aug 2024
In conjunction with this new offering, 23andMe, Lemonaid Health's parent company, recently launched study focused on the role genetics may play in effectiveness and side effects of GLP-1s In conjuncti
Why Eli Lilly is a top GLP-1 stock: Roundhill CEO
07:42pm, Tuesday, 27'th Aug 2024
Pharmaceutical companies have significantly grown over the last year as demand for GLP-1 weight-loss drugs continues to skyrocket. Roundhill Investments CEO Dave Mazza joins Market Domination for the
First Results from Lexaria's Second GLP-1 Human Pilot Study
09:20am, Tuesday, 27'th Aug 2024
Trend toward higher overall absorption under fed conditions evidenced with DehydraTECH®-processed Rybelsus® KELOWNA, BC / ACCESSWIRE / August 27, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ
